While proven to help, primary care clinicians have been slow to use the drugs once considered only for patients with diabetes.

The most recent version of NG28, the National Institute for Health and Care Excellence's (NICE) guidelines for managing type 2 diabetes in adults, has been released on February 18, 2026.

Most people with type 2 diabetes should be offered SGLT-2 inhibitors much earlier in their treatment, final NICE guidance has ...

Please provide your email address to receive an email when new articles are posted on . SGLT2 inhibitors were linked to lower risks for CKD and AKI but greater risks for albuminuria vs. GLP-1s. Risk ...

The global type 2 diabetes market size surpassed USD 40.09 billion in 2025 and is projected to reach approximately USD 79.25 ...

People diagnosed with type 2 diabetes before age 40 face a higher lifetime risk of heart and kidney problems, so may benefit from adding another type of medicine called a GLP-1 receptor agonist (such ...

Widely prescribing a newer class of drug for type 2 diabetes could save thousands of lives a year, according to a study. Researchers said once-a-day tablets called SGLT-2 inhibitors work “very well” ...

Despite the availability of effective antihypertensive therapies, global blood pressure control rates remain unacceptably low. Contributing factors, such as low treatment adherence, therapeutic ...

When you hear a word like “failure,” especially in the context of “heart failure,” it’s easy for your mind to turn dark. It sounds daunting and untreatable. Those are pretty scary thoughts (to ...

In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended1Results favored Vanrafia across multiple ...

Interest in the use and impacts of glucagon-like peptide-1 receptor agonists in rheumatology has exploded over the past year, a trend that appeared to crescendo at ACR Convergence 2025. There, ...